

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.*

康龍化成（北京）新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

**SUPPLEMENTAL ANNOUNCEMENT
FURTHER INFORMATION IN RELATION TO
THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2022**

Reference is made to the annual report of Pharmaron Beijing Co., Ltd.* (康龍化成（北京）新藥技術股份有限公司) (the “**Company**”) for the year ended December 31, 2022 (the “**2022 Annual Report**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the 2022 Annual Report.

In addition to the information disclosed the paragraph headed “Share Incentive Scheme” under the Directors’ Report and Note 40 to the consolidated financial statements as set out in the 2022 Annual Report, the Company would like to provide further details regarding the respective awards granted under the 2022 A Share Incentive Scheme and the First H Share Award and Trust Scheme during the Reporting Period pursuant to Rule 17.07(1)(c) of the Listing Rules.

The closing prices of the Shares of the Company immediately before the dates on which the awards were granted under the 2022 A Share Incentive Scheme and the First H Share Award and Trust Scheme during the Reporting Period are set out below:

2022 A SHARE INCENTIVE SCHEME

Date of grant	July 28, 2022
Closing price of the A Shares immediately before the date of grant	RMB82.37 <i>(Note)</i>

THE FIRST H SHARE AWARD AND TRUST SCHEME

Date of grant	April 1, 2022	May 31, 2022
Closing price of the H Shares immediately before the date of grant	HK\$63.28 <i>(Note)</i>	HK\$59.38 <i>(Note)</i>

Note: The respective closing prices took into account the impact of the 2021 Profit Distribution Plan which was implemented during the Reporting Period.

The above supplemental information does not affect other information contained in the 2022 Annual Report. Save as disclosed above, all other information in the 2022 Annual Report remains unchanged.

By order of the Board
Pharmaron Beijing Co., Ltd.*
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
August 4, 2023

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Hu Baifeng and Mr. Li Jiaqing as non-executive Directors; Mr. Zhou Qilin, Ms. Li Lihua, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.

* *For identification purposes only*